These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 30519392)
1. TUG1 confers cisplatin resistance in esophageal squamous cell carcinoma by epigenetically suppressing PDCD4 expression via EZH2. Xu C; Guo Y; Liu H; Chen G; Yan Y; Liu T Cell Biosci; 2018; 8():61. PubMed ID: 30519392 [TBL] [Abstract][Full Text] [Related]
2. TUG1 confers Adriamycin resistance in acute myeloid leukemia by epigenetically suppressing miR-34a expression via EZH2. Li Q; Song W; Wang J Biomed Pharmacother; 2019 Jan; 109():1793-1801. PubMed ID: 30551433 [TBL] [Abstract][Full Text] [Related]
3. HOXD-AS1 confers cisplatin resistance in gastric cancer through epigenetically silencing PDCD4 via recruiting EZH2. Ye Y; Yang S; Han Y; Sun J; Xv L; Wu L; Ming L Open Biol; 2019 Sep; 9(9):190068. PubMed ID: 31551012 [TBL] [Abstract][Full Text] [Related]
4. LncRNA TUG1 promotes cisplatin resistance in esophageal squamous cell carcinoma cells by regulating Nrf2. Zhang Z; Xiong R; Li C; Xu M; Guo M Acta Biochim Biophys Sin (Shanghai); 2019 Aug; 51(8):826-833. PubMed ID: 31287493 [TBL] [Abstract][Full Text] [Related]
5. Up-regulation of lncRNA CASC9 promotes esophageal squamous cell carcinoma growth by negatively regulating PDCD4 expression through EZH2. Wu Y; Hu L; Liang Y; Li J; Wang K; Chen X; Meng H; Guan X; Yang K; Bai Y Mol Cancer; 2017 Aug; 16(1):150. PubMed ID: 28854977 [TBL] [Abstract][Full Text] [Related]
6. EZH2 contributes to 5-FU resistance in gastric cancer by epigenetically suppressing FBXO32 expression. Wang C; Li X; Zhang J; Ge Z; Chen H; Hu J Onco Targets Ther; 2018; 11():7853-7864. PubMed ID: 30464532 [TBL] [Abstract][Full Text] [Related]
7. lncRNA TUG1 Promotes Cisplatin Resistance by Regulating CCND2 via Epigenetically Silencing miR-194-5p in Bladder Cancer. Yu G; Zhou H; Yao W; Meng L; Lang B Mol Ther Nucleic Acids; 2019 Jun; 16():257-271. PubMed ID: 30925453 [TBL] [Abstract][Full Text] [Related]
8. Long Non-Coding RNA Taurine Upregulated Gene 1 (TUG1) Downregulation Constrains Cell Proliferation and Invasion through Regulating Cell Division Cycle 42 (CDC42) Expression Via MiR-498 in Esophageal Squamous Cell Carcinoma Cells. Wang Z; Liu J; Wang R; Wang Q; Liang R; Tang J Med Sci Monit; 2020 Mar; 26():e919714. PubMed ID: 32139664 [TBL] [Abstract][Full Text] [Related]
9. Long non-coding RNA LINC00337 induces autophagy and chemoresistance to cisplatin in esophageal squamous cell carcinoma cells via upregulation of TPX2 by recruiting E2F4. Yang C; Shen S; Zheng X; Ye K; Ge H; Sun Y; Lu Y FASEB J; 2020 May; 34(5):6055-6069. PubMed ID: 32239565 [TBL] [Abstract][Full Text] [Related]
10. Hsa_circ_0007142 contributes to cisplatin resistance in esophageal squamous cell carcinoma via miR-494-3p/LASP1 axis. Chang N; Ge N; Zhao Y; Yang L; Qin W; Cui Y J Clin Lab Anal; 2022 May; 36(5):e24304. PubMed ID: 35312115 [TBL] [Abstract][Full Text] [Related]
11. LncRNA TUG1 contributes to ESCC progression via regulating miR-148a-3p/MCL-1/Wnt/β-catenin axis in vitro. Tang Y; Yang P; Zhu Y; Su Y Thorac Cancer; 2020 Jan; 11(1):82-94. PubMed ID: 31742924 [TBL] [Abstract][Full Text] [Related]
12. LncRNA TUG1 promotes tumor growth and metastasis of esophageal squamous cell carcinoma by regulating XBP1 via competitively binding to miR-498. Jin G; Yang Y; Tuo G; Wang W; Zhu Z Neoplasma; 2020 Jul; 67(4):751-761. PubMed ID: 32305055 [TBL] [Abstract][Full Text] [Related]
13. Circular RNA hsa_circ_0000277 promotes tumor progression and DDP resistance in esophageal squamous cell carcinoma. Cheng J; Zhang R; Yan M; Li Y BMC Cancer; 2022 Mar; 22(1):238. PubMed ID: 35241028 [TBL] [Abstract][Full Text] [Related]
14. High TUG1 expression is associated with chemotherapy resistance and poor prognosis in esophageal squamous cell carcinoma. Jiang L; Wang W; Li G; Sun C; Ren Z; Sheng H; Gao H; Wang C; Yu H Cancer Chemother Pharmacol; 2016 Aug; 78(2):333-9. PubMed ID: 27329359 [TBL] [Abstract][Full Text] [Related]
15. C-terminal binding protein‑2 mediates cisplatin chemoresistance in esophageal cancer cells via the inhibition of apoptosis. Shi H; Mao Y; Ju Q; Wu Y; Bai W; Wang P; Zhang Y; Jiang M Int J Oncol; 2018 Jul; 53(1):167-176. PubMed ID: 29658564 [TBL] [Abstract][Full Text] [Related]
16. lncRNA TUG1 inhibits the cancer stem cell‑like properties of temozolomide‑resistant glioma cells by interacting with EZH2. Cao Y; Chai W; Wang Y; Tang D; Shao D; Song H; Long J Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 34036375 [TBL] [Abstract][Full Text] [Related]
17. Upregulation of the long noncoding RNA TUG1 promotes proliferation and migration of esophageal squamous cell carcinoma. Xu Y; Wang J; Qiu M; Xu L; Li M; Jiang F; Yin R; Xu L Tumour Biol; 2015 Mar; 36(3):1643-51. PubMed ID: 25366138 [TBL] [Abstract][Full Text] [Related]
18. Low expression of TUG1 promotes cisplatin sensitivity in cervical cancer by activating the MAPK pathway. Wei X; Zhou Y; Qiu J; Wang X; Xia Y; Sui L J BUON; 2019; 24(3):1020-1026. PubMed ID: 31424656 [TBL] [Abstract][Full Text] [Related]
19. LINC00963 Promotes Cisplatin Resistance in Esophageal Squamous Cell Carcinoma by Interacting with miR-10a to Upregulate SKA1 Expression. Hu D; Ma A; Lu H; Gao Z; Yu Y; Fan J; Liu S; Wang Y; Zhang M Appl Biochem Biotechnol; 2024 Mar; ():. PubMed ID: 38507172 [TBL] [Abstract][Full Text] [Related]
20. Anticancer potential of TUG1 knockdown in cisplatin-resistant osteosarcoma through inhibition of MET/Akt signalling. Zhou Q; Hu T; Xu Y J Drug Target; 2020 Feb; 28(2):204-211. PubMed ID: 31305159 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]